Real-world long-term outcomes of advanced/metastatic NSCLC patients treated with EGFR TKIs in Nottinghamshire

被引：0
|
作者：
Lopez-Escola, C. [1 ]
Mengoli, K. [1 ]
Sheikh, O. [1 ]
Karim, S. [1 ]
Sadiq, M. [1 ]
机构：
[1] Nottingham Univ Hosp NHS Trust, Nottingham, England
来源：
LUNG CANCER | 2020年 / 139卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [31] Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
    Gounder, Mrinal M.
    Merriam, Priscilla
    Ratan, Ravin
    Patel, Shreyaskumar R.
    Chugh, Rashmi
    Villalobos, Victor M.
    Thornton, Mark
    Van Tine, Brian A.
    Abdelhamid, Amr H.
    Joshi, Preeti
    Whalen, Jennifer
    Yang, Jay
    Rajarethinam, Anand
    Duh, Mei Sheng
    Bobbili, Priyanka J.
    Huynh, Lynn
    Totev, Todor I.
    Lax, Angela K.
    Demetri, George D.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 300 - 300
  • [32] Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
    Li, Jia
    Han, Baohui
    Liu, Huaimin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
    Moulson, Ruth
    Law, Jennifer
    Sacher, Adrian
    Liu, Geoffrey
    Shepherd, Frances
    Bradburyb, Penelope
    Eng, Lawson
    Iczkovitz, Sandra
    Abbie, Erica
    Elia-Pacitti, Julia
    Ewara, Emmanuel M.
    Mokriak, Viktoriia
    Weiss, Jessica
    Pettengell, Christopher
    Leighl, Natasha
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E12 - E13
  • [34] Understanding real-world outcomes in patients with NSCLC who progress on 1st-/2nd-generation EGFR TKIs.
    Fernandes, Ancilla
    Skinner, Karen E.
    Walker, Mark Stephen
    Pavilack, Melissa
    Vanderwalde, Ari M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] REAL-WORLD LONG-TERM OVERALL SURVIVAL IN METASTATIC CANCER IN SWEDEN
    Butepage, G.
    Carlqvist, P.
    Subban, I. S.
    Jacob, J.
    Vertuani, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S249 - S249
  • [36] Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
    Apter, L.
    Moser, S. Sharman
    Wollner, M.
    Chodick, G.
    Siegelmann-Danieli, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S405 - S405
  • [37] Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
    Yao, Y.
    Cheng, J.
    Kang, J.
    Li, X.
    Chen, H.
    Zhou, Q.
    Xu, C.
    Zhang, X.
    Su, J.
    Yan, H.
    Wu, Y.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S671 - S671
  • [38] Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
    Igawa, S.
    Ono, T.
    Kasajima, M.
    Yamada, K.
    Oguri, A.
    Kameda, A.
    Yamamoto, H.
    Kakegawa, M.
    Hiyoshi, Y.
    Kusuhara, S.
    Ozawa, T.
    Otani, S.
    Fukui, T.
    Mitsufuji, H.
    Masaru, K.
    Yokoba, M.
    Kubota, M.
    Sasaki, J.
    Naoki, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S611 - S611
  • [39] Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
    Riely, Gregory J.
    Lovly, Christine Marie
    Messina, Carlo G. M.
    Bienert, Stefanie
    Alexander, Kimberly
    Pao, William
    Baxi, Shrujal
    Doebele, Robert Charles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC from Real-World Data (RWD)
    Garcia, M.
    Calles, A.
    Lobo, M.
    Alvarez Alvarez, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S612 - S612
12345